Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 8.61, representing a potential upside of 38.4% from the current price of HKD 6.22 [2]. Core Insights - The company has experienced a slowdown in sales growth in 2023, with revenue reaching CNY 31.45 billion, a year-on-year increase of 1.7%. The gross profit was CNY 22.18 billion, with a gross margin of 70.5%, down 1.4 percentage points [1][4]. - The company is focusing on innovation and transformation, with R&D expenses increasing by 21.2% to CNY 4.83 billion, accounting for 18.8% of the revenue from the pharmaceutical segment. Over the next five years, more than 50 new products or indications are expected to be approved [2][5]. - The company is expanding its product portfolio, particularly in the neurology sector, where revenue grew by 12.1% to CNY 9.09 billion, now accounting for 35.4% of the pharmaceutical revenue [1][2]. Financial Summary - In 2023, the pharmaceutical segment generated revenue of CNY 25.64 billion, up 4.6%, while the vitamin C raw materials segment saw a significant decline in revenue to CNY 1.93 billion, down 23.7% [1]. - The company reported a net profit of CNY 5.87 billion, a decrease of 3.6%, while the adjusted net profit increased by 2.8% to CNY 6.28 billion, with an adjusted net profit margin of 20.0% [1][4]. - The company’s market capitalization is HKD 732 billion, with a total issued share capital of 11.903 billion shares [2].
集采影响充分消化，明星产品保持潜力，创新转型将步入密集收获期